SpringerLink
Log in

Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19

  • Correspondence
  • Published:
Molecular Psychiatry Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kirenga BJ, Mugenyi L, Sanchez-Rico M, Kyobe H, Muttamba W, Mugume R, et al. Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a prospective interventional open-label cohort study. Mol. Psych. 2023;28:5411–8.

    Article  CAS  Google Scholar 

  2. Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, et al. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. JAMA. 2020;324:2292–300.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Reis G, Dos SME, Silva D, Thabane L, Milagres AC, Ferreira TS, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob. Health. 2022;10:e42–51.

    Article  CAS  PubMed  Google Scholar 

  4. Bramante CT, Huling JD, Tignanelli CJ, Buse JB, Liebovitz DM, Nicklas JM, et al. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. N. Engl. J. Med. 2022;387:599–610.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. McCarthy MW, Naggie S, Boulware DR, Lindsell CJ, Stewart TG, Felker GM, et al. Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2023;330:1589.

    Google Scholar 

  6. Arbel R, Wolff Sagy Y, Hoshen M, Battat E, Lavie G, Sergienko R, et al. Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge. N. Engl. J. Med. 2022;387:790–8.

    Article  CAS  PubMed  Google Scholar 

  7. Abraham T, Adcock K, Ahmed N, Ali A, Ali S, Allen K, et al. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet (Br. Ed.). 2023;401:1499–507.

    Google Scholar 

  8. Siripongboonsitti T, Ungtrakul T, Tawinprai K, Nimmol T, Buttakosa M, Sornsamdang G, et al. Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized controlled trial (EFFaCo study). Int. J. Infect. Dis. 2023;134:211–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. These authors contributed equally: Guangting Zeng, Jianqiang Li.

Authors and Affiliations

  1. Department of Pharmacy, The First People’s Hospital of Chenzhou, **angnan University, Chenzhou, China

    Guangting Zeng

  2. Department of Pharmacy, Taihe Hospital, Hubei University of Medicine, Shiyan, China

    Jianqiang Li

  3. Department of Pharmacy, Cancer Center(**amen), Fudan University, **amen, China

    Linlin Wang

  4. Department of Pharmacy, **angya Hospital, Central South University, Changsha, China

    Zanling Zhang

Authors
  1. Guangting Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jianqiang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Linlin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zanling Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Jianqiang Li and Zanling Zhang initiated and conceptualised the idea. Guangting Zeng wrote the letter, Linlin Wang revised the letter.

Corresponding author

Correspondence to Zanling Zhang.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zeng, G., Li, J., Wang, L. et al. Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19. Mol Psychiatry (2024). https://doi.org/10.1038/s41380-024-02635-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41380-024-02635-0

  • Springer Nature Limited

Search

Navigation